Evidence map›Paper›PMID 36058401›Full record

ArticleJournal of pain and symptom management2022

Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.

Mercy C Anyanwu, Onyinye Ohamadike, Lauren E Wilson, Clare Meernik, Bin Huang, Maria Pisu, Margaret Liang, Rebecca A Previs, Ashwini Joshi, Kevin C Ward and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of pain and symptom management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Mercy C AnyanwuDepartment of Internal Medicine (M.C.A.), Pennsylvania Hospital of the University of Pennsylvania, Pennsylvania, USA.
Onyinye OhamadikeDuke University School of Medicine (O.O.), Durham, North Carolina, USA.
Lauren E WilsonDepartment of Population Health Sciences (L.E.W., C.M., A.J., T.A.), Duke University School of Medicine, Durham, North Carolina, USA.
Clare MeernikDepartment of Population Health Sciences (L.E.W., C.M., A.J., T.A.), Duke University School of Medicine, Durham, North Carolina, USA.
Bin HuangDepartment of Biostatistics and Kentucky Cancer Registry (B.H., T.T.), University of Kentucky, Lexington Kentucky, USA.
Maria PisuDivision of Preventive Medicine and O'Neal Comprehensive Cancer Center (M.P., M.L.), University of Alabama at Birmingham, Birmingham, Alabama, USA.
Margaret LiangDivision of Preventive Medicine and O'Neal Comprehensive Cancer Center (M.P., M.L.), University of Alabama at Birmingham, Birmingham, Alabama, USA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology (M.L.), University of Alabama at Birmingham, Birmingham, Alabama, USA.
Rebecca A PrevisDivision of Gynecologic Oncology (R.A.P., A.B.), Duke Cancer Institute, Duke University School of Medicine, Durham North Carolina, USA.
Ashwini JoshiDepartment of Population Health Sciences (L.E.W., C.M., A.J., T.A.), Duke University School of Medicine, Durham, North Carolina, USA.
Kevin C WardGeorgia Cancer Registry (K.C.W.), Emory University, Atlanta Georgia, USA.
Tom TuckerDepartment of Biostatistics and Kentucky Cancer Registry (B.H., T.T.), University of Kentucky, Lexington Kentucky, USA.
Maria J SchymuraNew York State Cancer Registry, New York State Department of Health (M.J.S.), Albany New York, USA.
Andrew BerchuckDivision of Gynecologic Oncology (R.A.P., A.B.), Duke Cancer Institute, Duke University School of Medicine, Durham North Carolina, USA.
Tomi AkinyemijuDepartment of Population Health Sciences (L.E.W., C.M., A.J., T.A.), Duke University School of Medicine, Durham, North Carolina, USA; Duke Cancer Institute, Duke University School of Medicine (T.A.), Durham, North Carolina, USA. Electronic address: tomi.akinyemiju@duke.edu.
Duke University · USUniversity of Alabama at Birmingham · USUniversity of Kentucky · USEmory University · USHospital of the University of Pennsylvania · USNew York State Department of Health · US

Funding

Stress-related inflammation and racial disparities in ovarian cancerR37CA233777 · NCI · DUKE UNIVERSITY · PI AKINYEMIJU, TOMI F · 2019 to 2025
$4.2M
NCI NIH HHS R37 CA233777
6 · The paper itself

Abstract

objectiveLack of access to supportive care (SC) among cancer patients have been well documented. However, the role of affordability in this disparity among ovarian cancer (OC) patients remain poorly understood.

methodsPatients with OC between 2008 and 2015 were identified from the SEER-Medicare dataset. Racial disparities in utilization of SC medications within the six months of OC diagnosis among patients with Medicare Part D coverage was examined. Multivariable log-binomial regression models were used to examine the associations of race, affordability and SC medications after adjusting for clinical covariates among all patients and separately among patients with advanced-stage disease.

resultsThe study cohort included 3697 patients: 86% non-Hispanic White (NHW), 6% non-Hispanic Black (NHB), and 8% Hispanic. In adjusted models, NHB and Hispanic patients were less likely to receive antidepressants compared to NHW patients (NHB: aOR 0.46; 95% CI 0.33-0.63 and Hispanic: aOR 0.79; 95% CI 0.63-0.99). This association persisted for NHB patients with advanced-stage disease (aOR 0.42; 95% CI 0.28-0.62). Patients dual enrolled in Medicaid were more likely to receive antidepressants (overall: aOR 1.34; 95% CI 1.17-1.53 and advanced-stage: aOR 1.29; 95% CI 1.10-1.52). However, patients residing in areas with higher vs. lower proportions of lower educated adults (overall: aOR 0.82; 95% CI 0.70-0.97 and advanced-stage: aOR 0.82; 95% CI 0.68-0.99) were less likely to receive antidepressants.

conclusionBlack OC patients and those living in lower educated areas were less likely to receive antidepressants as SC. Given the importance of post-primary treatment quality of life for cancer patients, interventions are needed to enhance equitable access to SC.

Indexed as

Ovarian NeoplasmsWhite PeopleAdultAgedBlack or African AmericanCosts and Cost AnalysisFemaleHumansMedicareQuality of LifeUnited StatesHealth care affordabilityovarian cancerrace/ethnicitysupportive care

Identifiers

PMID36058401
PMCPMC10083071
OpenAlexW4294204274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.